IP : Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury -December 14, 2023 at 12:44 pm EST

14 Dec 2023



- Mission gains clearance from US FDA for Phase II trial of MTX652 after it receives official approval of its Investigational New Drug application
...

Related Keywords

United States ,America ,Mary Clark ,Stephen Adams ,Paul Thompson ,Anker Lundemose ,Suhail Nurbhai ,Mission Therapeutics Ltd ,Drug Administration ,Mission Therapeutics ,Ip Group ,Strategic Communications ,Roche Venture Fund ,Investigational New Drug ,Acute Kidney Injury ,North America ,Chief Executive Officer ,Chief Medical Officer ,Chief Scientific Officer ,Phasei First Time ,Ischaemic Reperfusion Injury ,Therapeutics Ltd ,Muscular Dystrophy ,Pfizer Venture Investments ,Sofinnova Partners ,Markets ,